¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¹ßÇ¥ÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ

ÀϹݿ¬Á¦ ¹ßÇ¥ À¯ÀÇ»çÇ×

ÀϹݿ¬Á¦ ¹ßÇ¥ÀÚ´Â ¹Ýµå½Ã ¹ßÇ¥ ½½¶óÀ̵å(ÆÄ¿öÆ÷ÀÎÆ®)¸¦ »çÀü¿¡ Á¦ÃâÇÏ¼Å¾ß ¹ßÇ¥°¡ °¡´ÉÇÕ´Ï´Ù.
½½¶óÀ̵带 ±âÇÑ ³»¿¡ Á¦ÃâÇÏÁö ¾ÊÀ» °æ¿ì¿¡´Â ¹ßÇ¥ºÒ°¡´ÉÀ¸·Î °£ÁÖÇÕ´Ï´Ù.
¹ßÇ¥ ½½¶óÀ̵å¼ö´Â 15¸Å À̳»·Î 1Àå ´ç 10ÁÙ À̳»·Î Á¦ÀÛÇϽô °ÍÀ» ±ÇÀåÇϸç, ÁöÁ¤µÈ 10ºÐ ¹ßÇ¥½Ã°£(8ºÐ ÅäÀÇ-2ºÐ ÁúÀÇÀÀ´ä)À» Á¤È®È÷ ÁöÄÑÁֽñ⠹ٶø´Ï´Ù.

1. ÆÄÀÏ Á¦Ã⸶°¨ÀÏ : 9¿ù 22ÀÏ (¿ù)
2. ÆÄÀÏ ÇüÅ : ÆÄ¿öÆ÷ÀÎÆ®
3. Á¦Ãâ ¹æ¹ý : ppt1@ksog.org

±¸¿¬ - Àüü   /    ¸ðüžÆÀÇÇР  /    »ý½Ä³»ºÐºñÇР  /    ºÎÀÎÁ¾¾çÇР  /    ÀϹݺÎÀΰúÇÐ

[ ±¸¿¬ - ¸ðüžÆÀÇÇÐ ]

2008³â 9¿ù 26ÀÏ(±Ý)

Convention Hall A (4F)
½Ã°£ ¹øÈ£ ¼º¸í ¼Ò¼Ó Á¦¸ñ
ÁÂÀå : ¹ÚÀ±±â(¿µ³²ÀÇ´ë)
12:30~13:10 OB1 ±èÈÖ°ï ºÎ»êÀÇ´ë Postnatal neovascularization in a mouse model via stem cells derived from human fetal amniotic membranes
OB2 °­¿µÈ­ °¡Å縯ÀÇ´ë Omcostatin M as a target biological molecule of preeclampsia
OB3 °ûµ¿¿í ¿¬¼¼ÀÇ´ë Leukocyte counts and differential distribution in preeclampsia
OB4 ÁÖº¸¼± ÁÁÀº¹®È­º´¿ø ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®°¡ Àΰ£ ¾ç¼öÀ¯·¡ Áß°£¿± Áٱ⼼Æ÷·ÎºÎÅÍ Á¶°ñ¼¼Æ÷¿Í Áö¹æ¼¼Æ÷·ÎÀÇ ºÐÈ­¿¡ ¹ÌÄ¡´Â ¿µÇâ
ÁÂÀå : ½ÅÁ¾Ã¶(°¡Å縯ÀÇ´ë)
13:10~13:50 OB5 À̼ø¾Ö °æ»óÀÇ´ë Omega-3 fatty acids increase PPAR¥ã activity and Suppress ET-1 in human umbilical vein endothelial cells
OB6 ¹éÀ¯Áø °í·ÁÀÇ´ë Effect of Interferon-gamma on VEGF expression of extravillous trophoblast in first trimester villous explant culture
OB7 ¾ÈÇö¿µ °¡Å縯ÀÇ´ë Human placental membrane : a extensive source for mesenchymal stem cells with differentiation into osteocyte, chondrocyte, and adipocyte in vitro
OB8 ÀÌÁ¤Çå ÀüºÏÀÇ´ë Molecular mechanism for actin cleavage in rat uterus during pregnancy
ÁÂÀå : Á¶¿ë±Õ(ÀÎÁ¦ÀÇ´ë)
13:50~14:30 OB9 ÇÑÀ¯Á¤ °üµ¿ÀÇ´ë Karyotype and outcome of fetuses with increased nuchal translucency above 99th percentile
OB10 ÀÌ°æ¾Æ ¼­¿ïÀÇ´ë ¸¸»è Àӽſ¡¼­ ¾ç¼ö³» ź¯ Âø»öÀÇ ºóµµ¿Í À§ÇèÀÎÀÚ
OB11 ¹Ú¹®ÀÏ ÇѾçÀÇ´ë ºñ¼öÃ༺°Ë»ç¿¡¼­ žƽɹڵ¿ Áõ°¡½Ã ÁøÆø(bpm) ¹× Áö¼Ó½Ã°£(sec)ÀÇ ÀÇÀÇ
OB12 ¹Ú¹®ÀÏ ÇѾçÀÇ´ë ºñ¼öÃ༺°Ë»ç(NST) Æǵ¶¿¡¼­ ÀüÅëÀû ¼±Çü(linear) ºÐ¼®¹æ¹ý ¹× ºñ¼±Çü(nonlinear)ºÐ¼®¹æ¹ýÀÇ ºñ±³
14:30~15:00   Coffee Break
ÁÂÀå : Á¤Àιè(¿¬¼¼ÀÇ´ë)
15:00~15:40 OB13 ÀÌÀÏÇÑ Áß¾ÓÀÇ´ë Usefulness of umbilical cord arterial blood lactate for assessment of fetal metabolic acidemia
OB14 ±èÀÇÇõ ±¹¹Î°Ç°­º¸Çè°ø´Ü Àϻ꺴¿ø ÁøÅë Áß ·¹¹ÌÆ柴Ò(remifentanyl)À» ÀÌ¿ëÇÑ »ê¸ðÀÇ ÅëÁõ Á¶Àý
OB15 ±èÁ¾¿î Àü³²ÀÇ´ë ±â¿ÕÁ¦¿ÕÀý°³¼ú ÀÓºÎÀÇ ÀӽŠÁ¦2»ïºÐ±â ÁßÀý¿¡¼­ Áú³» ¹Ì¼ÒÇÁ·Î½ºÅç Åõ¿©¿Í ¶ó¹Ì³ª¸®¾Æ »ðÀÔ ÈÄ ½ÃµµÀÇ À¯¿ë¼º ºñ±³
OB16 À̽ÿø °üµ¿ÀÇ´ë The maternal bone mineral density (BMD) at second trimester of pregnancy can reflect the fetal growth at birth
ÁÂÀå : ÀÌÇÊ·®(¿ï»êÀÇ´ë)
15:40~16:20 OB17 ÁöÇö¿µ ¼º±Õ°üÀÇ´ë Frequency and risk factors for subsequent diabetes after gestational diabetes mellitus
OB18 ¼Õ°¡Çö ¿¬¼¼ÀÇ´ë Maternal lipids as predictive factors for large for gestational age newborns in women with gestational diabetes mellitus
OB19 ±èÁöÀ± ÀÌÈ­ÀÇ´ë ÀÓ½ÅÀü üÁú·®Áö¼ö¿Í ÀÓ½ÅÁß Ã¼ÁßÁõ°¡°¡ ÀӽŰá°ú¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ °üÇÑ ¿¬±¸
OB20 ¹éÀ¯Áø °í·ÁÀÇ´ë 100g °æ±¸ ´çºÎÇÏ °Ë»ç¹ýÀÇ º¯ÇüÀ» ÅëÇÑ Àӽżº ´ç´¢º´ÀÇ Áø´Ü
ÁÂÀå : È«±â¿¬(¿ø±¤ÀÇ´ë)
16:20~17:00 OB21 ±è¿¬Èñ °¡Å縯ÀÇ´ë Association of haptoglobin polymorphism with premature rupture of membrane
OB22 °­ÁöÇö ¼­¿ïÀÇ´ë ÀڱðæºÎ ºÐºñ¹°³» ÅÂ¾Æ ÆÄÀ̺ê·Î³Øƾ: Á¶±â ÁøÅë »ê¸ð¿¡¼­ÀÇ ¾ç¼ö³» ¿°Áõ ¹× ÅÂ¹Ý ¿°Áõ, Á¶»êÀÇ ¿¹ÃøÀÎÀÚ
OB23 ±è¹Î±Õ ¿ï»êÀÇ´ë Progesterone modulation of interleukin 6 in uterine cervical fibroblast cells of pregnant women treated with lipopolysaccharide
OB24 ±è¹ÎÇü °üµ¿ÀÇ´ë Amniotic and cervical fluid hyaluronic acid levels at mid-trimester and spontaneous preterm delivery


[ ±¸¿¬ - »ý½Ä³»ºÐºñÇÐ ]

2008³â 9¿ù 26ÀÏ(±Ý)

Convention Hall B (4F)
½Ã°£ ¹øÈ£ ¼º¸í ¼Ò¼Ó Á¦¸ñ
ÁÂÀå : ±è±âÅÂ(ÀÎÁ¦ÀÇ´ë)
12:30~13:10 RE1 ±èÇý¿¬ ¿¬¼¼ÀÇ´ë Ovarian reserve after laparoscopic enucleation of benign ovarian cysts
RE2 ÃÖ¿µ½Ä ¿¬¼¼ÀÇ´ë Effects of LNG-IUD on nerve growth factor and its receptors expression in patients with adenomyosis
RE3 ³²¾È³ª ¿¬¼¼ÀÇ´ë Expression of nonsteroidal anti-inflammatory drug-activated gene 1 (NAG-1) on the eutopic endometrium of the patients with endometriosis
RE4 ÀÌÇâ¾Æ °­¿øÀÇ´ë ³ì»ö Çü±¤ ¹ßÇö Á㸦 ÀÌ¿ëÇÑ È÷½ºÅæ µð¾Æ¼¼Æ¿·¹ÀÌÁî ¾ïÁ¦ÀçÀÇ Àڱà ³»¸·Áõ ¼¼Æ÷ Áõ½Ä ¾ïÁ¦¿¡ °üÇÑ ¿¬±¸
ÁÂÀå : ±è¼ºÇÑ(°í½ÅÀÇ´ë)
13:10~13:50 RE5 Á¤¹ÎÁö °æºÏÀÇ´ë Àڱ󻸷Áõ ȯÀÚÀÇ Àڱ󻸷¿¡¼­ LITAF (LPS induced TNF-alpha factor)ÀÇ ¹ßÇö Áõ°¡
RE6 Á¶½ÃÇö ¿¬¼¼ÀÇ´ë Neutrophil-lymphocyte ratio as an adjunct to CA-125 for the diagnosis of endometriosis
RE7 Á¶¿¬Áø °üµ¿ÀÇ´ë The impact of body mass index on the outcome of IVF/ICSI in patients with polycystic ovarian syndrome
RE8 ÀÌÇöÁÖ °üµ¿ÀÇ´ë Efficacy of intravenous immunoglobulin infusion in patients with repeated implantation failure who elevated circulating Natural Killer cells
ÁÂÀå : ±è¼ö³ç(°Ç±¹ÀÇ´ë)
13:50~14:30 RE9 À̼º±â °Ç¾çÀÇ´ë ¹Ýº¹À¯»ê ȯÀÚÀÇ ¼¼Æ÷¼º ¸é¿ªÀÇ Æ¯Â¡
RE10 Á¶½ÃÇö ¿¬¼¼ÀÇ´ë Evaluation of osteopontin expression in the eutopic endometrium and plasma osteopontin levels in patients with endometriosis
RE11 ±è¾Æ¸® Æ÷õÁß¹®ÀÇ´ë Impact of endometrium on pregnancy rate after intrauterine insemination.
RE12 ¹ÚÇöÅÂ °í·ÁÀÇ´ë Associations of endogenous sex hormones with metabolic syndrome and adipocytokine in postmenopausal women : Is androgen excess an inflammatory status in postmenopausal women ?
14:30~15:00   Coffee Break
ÁÂÀå : ±èÈ«¹è(ÇѸ²ÀÇ´ë)
15:00~15:40 RE13 ±è¹ÎÁö °üµ¿ÀÇ´ë Increased pregnancy rates after frozen embryo transfer with intravenous immunoglobulin treatment in women with repeated implantation failure
RE14 ÀÌ°æ¿í °í·ÁÀÇ´ë 3T3-L1 Áö¹æ¼¼Æ÷¿¡¼­ Lipoprotein lipaseÀÇ ¹ßÇö Á¶Àý¿¡ ´ëÇÑ ¿¡½ºÆ®·Î°Õ ¼ö¿ëüÀÇ ¿ªÇÒ
RE15 ÁÖÁ¾±æ ºÎ»êÀÇ´ë The effects of leptin on in vitro development of mouse embryos
RE16 À̼º±â °Ç¾çÀÇ´ë ¿ù°æ Áֱ⿡ µû¸¥ ¸é¿ª¼¼Æ÷ÀÇ º¯È­
ÁÂÀå : ÀÌżº(´ë±¸°¡Å縯ÀÇ´ë)
15:40~16:20 RE17 ±è¼Ò¶ó ¿ï»êÀÇ´ë Down-regulation of p21-activated kinase 1 (Pak1) by progestin and its increased expression in endometriotic cyst and adenomyotic nodule
RE18 ÃÖ¿øÁØ °æ»óÀÇ´ë Influence of the vitrification solution on the vascular endothelial growth factor of vitrified mouse ovarian tissue
RE19 ÃÖÇöÁø ¼º±Õ°üÀÇ´ë Impact of exogenous hormones on mammographic density in korean postmenopausal women
RE20 ÀÌ»ç¶ó ÀÌÈ­ÀÇ´ë Increased expression of glutathione by estradiol, tumor necrosis factor-alpha, and interleukin 1-beta in endometrial stromal cells
ÁÂÀå : ¹ÚÂù¿ë(°¡ÃµÀÇ´ë)
16:20~17:00 RE21 ¾È±âÈÆ °í·ÁÀÇ´ë Is hormone therapy associated with abnormal squamous cytology of the cervix in postmenopausal women?
RE22 ¾È±âÈÆ °í·ÁÀÇ´ë The effect of adiponectin and sex steroids on bone mineral density and bone turnover markers in postmenopausal women with endogenous subclinical hyperthyroidism
RE23 ÁÖÁ¾±æ ºÎ»êÀÇ´ë Relationships between uterine blood flow and pregnancy outcomes and serum E2 concentrations during in vitro fertilization
RE24 ±èÁö¿µ ¿ï»êÀÇ´ë ¹Ì¼º³â ¿©¾Æ¿Í ¹ÌÈ¥ ¿©¼º¿¡¼­ÀÇ ¹«¿ù°æÀÇ ¿øÀÎ


[ ±¸¿¬ - ºÎÀÎÁ¾¾çÇÐ ]

2008³â 9¿ù 26ÀÏ(±Ý)

Convention Hall C (4F)
½Ã°£ ¹øÈ£ ¼º¸í ¼Ò¼Ó Á¦¸ñ
ÁÂÀå : ¹é¿ø¿µ(°æ»óÀÇ´ë)
12:30~13:10 GO1 ÁÖ¿õ ÀÌÈ­ÀÇ´ë TP 53 restoration using E6/E7 siRNA potentiates therapeutic effect of cisplatin in cervical squamous cell carcinoma
GO2 À̼ºÁ¾ °¡Å縯ÀÇ´ë Distribution of human papillomavirus type 58 variants in progression of cervical dysplasia in Korean women
GO3 Àü½Ã¿ø ÀÌÈ­ÀÇ´ë The association between MCP-1 and CCR2 single nucleotide polymorphisms and cervical intraepithelial neoplasia and cervical cancer in Korean women
GO4 Á¶ÇѺ° ¿¬¼¼ÀÇ´ë Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumor marker for cervical neoplasia
ÁÂÀå : ÇãÁØ¿ë(°í·ÁÀÇ´ë)
13:10~13:50 GO5 ÀÌ´ë¿ì ¿¬¼¼ÀÇ´ë Clinical significance of tumor volume and lymph node involvement assessed by MRI in cervical cancer patients treated with concurrent chemotherapy and radiotherapy
GO6 ÀÌÀ¯¿µ ¼º±Õ°üÀÇ´ë The role of the maximal standardized uptake value (SUVmax) in positron emission tomography (PET) in early cervical cancer
GO7 ±èÀ±È¯ ¼­¿ïÀÇ´ë Adjuvant concurrent chemoradiotherapy-induced neutropenia as a prognostic factor in high-risk cervical cancer
GO8 ±èÈñ½Â ¼­¿ïÀÇ´ë Matched-case comparison for the role of surgery in FIGO stage Ib1-IIa squamous cell carcinoma of cervix and suspicious para-aortic lymph node metastasis
ÁÂÀå : ¿À¼ºÅÃ(Àü³²ÀÇ´ë)
13:50~14:30 GO9 °­Èñ¼® ¼º±Õ°üÀÇ´ë Relative high dose topotecan combined with carboplatin in recurrent epithelial ovarian cancer (EOC)
GO10 ±è¼öÇö Æ÷õÁß¹®ÀÇ´ë Gemcitabine-carboplatin-paclitaxel combination as first-line chemotherapy in advanced ovarian cancer
GO11 À̼ºÇÏ °¡Å縯ÀÇ´ë Serial pattern of CA125 levels as a predictive value of recurrence in advanced epithelial ovarian cancer
GO12 ±è¹Ì°æ ¼­¿ïÀÇ´ë Neoadjuvant chemotherapy for stage III or IV ovarian cancer : Effects on optimal debulking rates and survival
14:30~15:00   Coffee Break
ÁÂÀå : ±èÀåÈí(°¡Å縯ÀÇ´ë)
15:00~15:40 GO13 ¹ÚÁ¤¿­ ¿ï»êÀÇ´ë Comparison of laparoscopic radical hysterectomy and abdominal radical hysterectomy for stage IA2-IIA cervical cancer: A matched case-control study
GO14 À±Á¾¼÷ °¡Å縯ÀÇ´ë Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer
GO15 ¹ÚÁø¿µ ¾ÆÁÖÀÇ´ë Are the adjuvant chemoradiation using 3 ~ 4 cycles of 5-FU/Cisplatin adequate enough for all cervical cancer patients with high risk for treatment failure after radical hysterectomy?
GO16 °­¿ì´ë Àü³²ÀÇ´ë A clinical analysis of abnormal cervical cancer screening in private clinics
ÁÂÀå : ·ùöÈñ(ÀüºÏÀÇ´ë)
15:40~16:20 GO17 ±è±âÇü ºÎ»êÀÇ´ë AZD6244 (ARRY-142886), a Potent MEK 1/2 Inhibitor, induces Selective Growth inhibition in Epithelial Ovarian cancer cells
GO18 À̼±ÁÖ °Ç±¹ÀÇ´ë Combined effect of protein kinase B inhibitor or extracellular signal-regulated kinase inhibitor against farnesyltransferase inhibition-induced apoptosis in SiHa cells
GO19 Àü¼· ¼øõÇâÀÇ´ë Promoter methylation of runx3 gene in endometrial cancer
GO20 ½Å¼ÒÁø °è¸íÀÇ´ë Enhanced expression of transcription factor Nrf2 by isoliquiritigenin (ISL) in uterine leiomyoma cells.
ÁÂÀå : ±è¼®Çö(¼­¿ïÀÇ´ë)
16:20~17:00 GO21 ÇÑÈ£¼· °üµ¿ÀÇ´ë Laparoscopic-assisted vaginal hysterectomy vs. abdominal hysterectomy in endometrial cancer
GO22 Àü¿µÀº ¿¬¼¼ÀÇ´ë Leukocyte differential count as a diagnostic and prognostic factor in endometrial cancer
GO23 ±è¹ÎÁ¤ ¼­¿ïÀÇ´ë What do Korean breast cancer patients need for sexual activity?
GO24 ±â°æµµ °æÈñÀÇ´ë Pulmonary toxicity after a quick course of combinatorial vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy in cervical cancer

[ ±¸¿¬ - ÀϹݺÎÀΰúÇÐ ]

2008³â 9¿ù 26ÀÏ(±Ý)

Diamond Hall (3F)
½Ã°£ ¹øÈ£ ¼º¸í ¼Ò¼Ó Á¦¸ñ
ÁÂÀå : ÀÌÁ¤È£(°è¸íÀÇ´ë)
12:30~13:10 GG1 ¹ÚÁÖÇö ¿¬¼¼ÀÇ´ë The expression of vascular endothelial growth factor, angiopoietin 1 and 2 in eutopic and ectopic endometrium in adenomyosis
GG2 ±èÀ±È¯ ¼­¿ïÀÇ´ë 3D CT scan mapping of aortic bifurcation and inferior epigastric vessels for laparoscopy
GG3 ±èÈñ½Â ¼­¿ïÀÇ´ë Risk factors for disease recurrence after laser vaporization of lesions in the vaginal vault
GG4 À¯ÀºÈñ °æÈñÀÇ´ë Relationships between obstructive voiding symptoms, uroflowmetry and pressure flow studies
ÁÂÀå : ÀÌÅÃÈÄ(°æºÏÀÇ´ë)
13:10~13:50 GG5 À¯ÀºÈñ °æÈñÀÇ´ë Clinical study of the relationship between vesical volume at which VLPP was measured at first on urodynamic study and severity, QoL of urodynamic stress incontinence
GG6 À¯·¡¹Ì ¿ï»êÀÇ´ë Complications of hysteroscopic surgery in gynecology; Analysis of frequency and risk factors on 1217 cases at single institution
GG7 À±Á¤¼· °üµ¿ÀÇ´ë °ñ¹ÝÀå±âÅ»ÃâÁõ ȯÀÚ¿¡¼­ ÀÚ±Ãõ°ñÀδë ÄݶóÁ¨ I ¹× ÄݶóÁ¨ III ¹ßÇö
GG8 Á¤ÇöÁÖ ¿¬¼¼ÀÇ´ë Preoperative maximum urethral closure pressure and valsalva leak point pressure as predictive parameters for midurethral sling
ÁÂÀå : ÃÖ»óÁØ(Á¶¼±ÀÇ´ë)
13:50~14:30 GG9 ½ÅÁ¤È£ °í·ÁÀÇ´ë Anterior transobturator polypropylene mesh in the correction of anterior vaginal wall prolapse: 2-points, half-sized method vs. 4-points, full-sized method
GG10 ±èÁÖ¸í °üµ¿ÀÇ´ë Abdominal hysterectomy: Can we decrease the number?
GG11 ³²ÁÖÇö ¿ï»êÀÇ´ë Laparoscopic-assisted vaginal hysterectomy and laparoscopic adenxal surgery using ¡°Two-port laparoscopy system¡±
GG12 Àü¸íÀç ¼­¿ïÀÇ´ë º¹½Ä õ°ñÁú°íÁ¤¼úÀÇ Àå±â Ä¡·á¼ºÀû
14:30~15:00   Coffee Break
ÁÂÀå : ¹ÚÁø¿Ï(´Ü±¹ÀÇ´ë)
15:00~15:40 GG13 Á¤ÇöÁÖ ¿¬¼¼ÀÇ´ë ³»Àμº °ý¾à±Ù ±â´É ºÎÀüÀÇ ¿ä¿ªµ¿ÇÐ °Ë»ç»ó Ư¡Àû ¼Ò°ß
GG14 Á¶Çý¿¬ Àü³²ÀÇ´ë Á¤»ó°ú ¼¼±ÕÁúÁõ ¿©¼º¿¡¼­ °ú»êÈ­¼ö¼Ò»ý¼º À¯»ê±ÕÀ» Áú³» Åõ¿© ÈÄ Áú °ú»êÈ­¼ö¼Ò »ý¼º º¯È­ ¹× Ä¡·á È¿°ú
GG15 ±ÇÀçÇö ¿¬¼¼ÀÇ´ë °ñ¹Ý Àå±â Å»ÃâÁõ ¹× ¿ä½Ç±ÝÀÇ ¿¹ÈÄ ÀÎÀڷμ­ÀÇ »ê°ú·ÂÀÌ °¡Áö´Â ÀÇÀÇ
GG16 ÀÌ¹Ì°æ ¿¬¼¼ÀÇ´ë The influence of obesity on outcomes of surgical treatment of stress urinary incontinence
ÁÂÀå : Â÷¹®¼®(µ¿¾ÆÀÇ´ë)
15:40~16:20 GG17 ±è¹Ì¶ó °üµ¿ÀÇ´ë ½Ä¿°¼ö ÁÖÀÔ Àڱ󻸷 Á¶¿µ¼ú·Î È®ÀÎÇÑ Àڱà ³»¸· Æú¸³ÀÇ º¯È­ ¾ç»ó ºñ±³
GG18 ±èÇöÁ¤ °¡Å縯ÀÇ´ë ¼±Ãµ¼º Àڱà ±âÇü 110¿¹¿¡ ´ëÇÑ ÀÓ»óÀû °íÂû
GG19 À̸¶¸®¾Æ ¿¬¼¼ÀÇ´ë Outcome of Mid urethral procedures according to age
GG20 ¹ÚÁ¤¿­ ¿ï»êÀÇ´ë Risk factors for recurrence after laparoscopic conservative surgery in premenopausal women with previously untreated stage III-IV ovarian endometriomas
ÁÂÀå : À̺¸¿¬(°æÈñÀÇ´ë)
16:20~17:00 GG21 ¹ÚÇö Æ÷õÁß¹®ÀÇ´ë The safety and efficacy of MR-guided focused ultrasound surgery in the treatment of pedunculated subserosal myomas of the uterus: Preliminary report.
GG22 ³²ÀåÇö ³²ÀåÇö »êºÎÀΰú Vaginal myomectomy for intracavitary pedunculated myomas after ultrasound-guided transvaginal HiTT(High frequency induced Thermotherapy)
GG23 Á¤ÇöÁÖ ¿¬¼¼ÀÇ´ë °ñ¹ÝÀå±â Å»ÃâÁõ ±³Á¤¼úÀ» ½ÃÇà ¹ÞÀº ȯÀÚ¿¡¼­ ¹ß»ýÇÑ ¼ö¼ú ÈÄ ¹è´¢Àå¾Ö
GG24 ÀÓ°æÁø ¿¬¼¼ÀÇ´ë Postpartum urinary retention after vaginal delivery